Skip to content
Blerp – Lifestyle
Author:
Classover Holdings Inc.
Classover Reports First Quarter 2026 Results and Accelerates Transition Toward AI-Native Intelligent Robotics Ecosystems and Next-Generation Education Platforms
May 15, 2026
Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
May 13, 2026
Classover Launches Embodied AI Robotics Education Platform Featuring Proprietary Curriculum Built on Advanced Humanoid Robotics Systems
May 11, 2026
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
May 7, 2026
Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
May 5, 2026
Classover Announces Strategic Collaboration With Vensin Computer Technology To Advance AI Robotics Education and Infrastructure
May 4, 2026
Classover and Harvard-Incubated Marbella AI Announce Strategic Partnership to Advance AI Education
April 29, 2026
Classover Named to TIME’s America’s Top EdTech Companies of 2026
April 27, 2026
Classover Enters Strategic Collaboration with ICreate Education Technology to Advance AI Robotics Learning in North America
April 22, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
April 16, 2026
←
Previous Page
1
2
3
4
Next Page
→